ArticleBMC pharmacology & toxicology2025
Hepatic modulation of apelin and galectin-3 by darbepoetin-alpha in Dexamethasone induced insulin-resistant rats.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin resistance (IR) is a central pathological mechanism underlying metabolic syndrome and associated disorders, including type 2 diabetes and non-alcoholic fatty liver disease. This study investigated the therapeutic effects of darbepoetin alfa (DA), an erythropoietin analogue, in a dexamethasone (Dexa)-induced IR model, focusing on its impact on metabolic regulation (apelin) and inflammatory pathways (galectin-3) in liver tissue. MATERIALS AND
methodsThirty-two male Wistar rats were divided into four groups (n = 8/group): (saline 1 ml/kg/day intraperitoneal [ip] for 5 days), IR (Dexa 1 mg/kg/day ip for 5 days), DA (single 5 µg/kg ip dose on day 6), and IR + DA (Dexa followed by DA). Body weight, fasting glucose, insulin levels, and HOMA-IR were assessed. Liver function was evaluated via AST/ALT levels, while histopathological changes (hydropic degeneration, necrosis, fibrosis via Masson’s trichrome) and immunohistochemical expression of apelin and galectin-3 were analyzed.
resultsThere were no significant differences in body weights between groups; only the IR group experienced weight loss. Fasting glucose and HOMA-IR levels were significantly higher in the IR group (p < 0.001, p = 0.008), while insulin levels showed no significant change. Darbepoetin treatment reduced glucose and HOMA-IR. Histologically, the IR group displayed marked hepatocyte degeneration, lipid accumulation, necrosis, and disorganized hepatic cords. Masson’s Trichrome staining showed increased collagen deposition around vessels in the IR group, which was reduced after darbepoetin. Immunohistochemically, apelin expression was significantly decreased and galectin-3 increased in the IR group compared to SHAM (p < 0.001). These changes were reversed in the IR + DA group. The SHAM and DA groups exhibited normal liver architecture without pathological alterations.
conclusionDA attenuated Dexa-induced IR by improving glycemic control, reducing hepatic injury, and modulating key metabolic (apelin↑) and inflammatory (galectin-3↓) markers. The restoration of liver histopathology and reduction in fibrosis suggest DA’s potential as a multifunctional agent against IR-associated complications. Further studies are needed to validate these findings in chronic models and clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.